Whole-genome sequencing to control antimicrobial resistance

Trends in Genetics

Volumn 30, Issue 9, 2014, Pages 401-407

  Köser, Claudio U ^a   Ellington, Matthew J ^b   Peacock, Sharon J ^a,b,c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Antibiotic resistance; Diagnostics; Surveillance; Whole genome sequencing

Indexed keywords

ANTIBIOTIC AGENT; BEDAQUILINE; CARBAPENEMASE; CHLORAMPHENICOL; DOXYCYCLINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; OFLOXACIN; PENICILLIN BINDING PROTEIN 2A; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; GENE SEQUENCE; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; BACTERIAL INFECTIONS; GENETICS; GENOMICS; PROCEDURES;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; GENOMICS; HUMANS;

EID: 85027956307     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2014.07.003     Document Type: Review

References (100)

1. Antibiotic Resistance Threats in the United States, 2013 2013, Centers for Disease Control and Prevention, US Department of Health and Human Services.
2. Davies S.C. Annual Report of the Chief Medical Officer. Volume II: Infections and the Rise of Antibiotic Resistance 2011, The Stationery Office. D. Walker, T. Fowler (Eds.).
3. WHO The Evolving Threat of Antimicrobial Resistance - Options for Action 2012, World Health Organization.
4. Livermore D.M., Wain J. Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship. Infect. Chemother. 2013, 45:1-10.
5. Spellberg B., et al. The future of antibiotics and resistance. N. Engl. J. Med. 2013, 368:299-302.
6. Loman N.J., et al. High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity. Nat. Rev. Microbiol. 2012, 10:599-606.
7. Loman N.J., et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat. Biotechnol. 2012, 30:434-439.
8. Harris S.R., et al. Read and assembly metrics inconsequential for clinical utility of whole-genome sequencing in mapping outbreaks. Nat. Biotechnol. 2013, 31:592-594.
9. Köser C.U., et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog. 2012, 8:e1002824.
10. Köser C.U., et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N. Engl. J. Med. 2012, 366:2267-2275.
11. Köser C.U., et al. Rapid single-colony whole-genome sequencing of bacterial pathogens. J. Antimicrob. Chemother. 2014, 69:1275-1281.
12. Chewapreecha C., et al. Dense genomic sampling identifies highways of pneumococcal recombination. Nat. Genet. 2014, 46:305-309.
13. Nasser W., et al. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1768-E1776.
14. Didelot X., et al. Transforming clinical microbiology with bacterial genome sequencing. Nat. Rev. Genet. 2012, 13:601-612.
15. Roemer T., Boone C. Systems-level antimicrobial drug and drug synergy discovery. Nat. Chem. Biol. 2013, 9:222-231.
16. Zumla A., et al. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12:388-404.
17. Andries K., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
18. Feuerriegel S., et al. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J. Antimicrob. Chemother. 2014, 69:1205-1210.
19. Köser C.U., et al. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob. Agents Chemother. 2012, 56:6080-6087.
20. Feuerriegel S., et al. Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob. Agents Chemother. 2011, 55:5718-5722.
21. Bagcchi S. Novel drug combination for tuberculosis to be tested across 50 sites. BMJ 2014, 348:g3535.
22. Müller B., et al. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 2013, 29:160-169.
23. Hartkoorn R.C., et al. Cross-resistance between clofazimine and bedaquiline through up-regulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58:2979-2981.
24. Niemann S., et al. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS ONE 2009, 4:e7407.
25. Eyre D.W., et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of Infection with Clostridium difficile. J. Infect. Dis. 2014, 209:1446-1451.
26. Dettman J.R., et al. Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:21065-21070.
27. Bryant J.M., et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir. Med. 2013, 1:786-792.
28. Menzies D. Molecular methods for tuberculosis trials: time for whole-genome sequencing?. Lancet Respir. Med. 2013, 1:759-761.
29. Grundmann H. Towards a global antibiotic resistance surveillance system: a primer for a roadmap. Ups J. Med. Sci. 2014, 119:87-95.
30. Grad Y.H., et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect. Dis. 2014, 14:220-226.
31. Bryant J.M., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013, 381:1551-1560.
32. Mycobacterium abscessus. Suggestions For Infection Prevention and Control (Interim guidance - October 2013) 2013, Mycobacterium abscessus Infection Control Working Group, Cystic Fibrosis Trust.
33. Tettelin H., et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg. Infect. Dis. 2014, 20:364-371.
34. Harris S.R., et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010, 327:469-474.
35. Holden M.T., et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 2013, 23:653-664.
36. He M., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 2012, 45:109-113.
37. Mather A.E., et al. Distinguishable epidemics of multidrug-resistant Salmonella Typhimurium DT104 in different hosts. Science 2013, 341:1514-1517.
38. Price L.B., et al. Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. MBio 2012, 3:e00305-e311.
39. Palmer A.C., Kishony R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat. Rev. Genet. 2013, 14:243-248.
40. Toprak E., et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 2012, 44:101-105.
41. Safi H., et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-beta-D-arabinose biosynthetic and utilization pathway genes. Nat. Genet. 2013, 45:1190-1197.
42. Ando H., et al. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol. Microbiol. 2014, 91:538-547.
43. Gagneux S., Small P.M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 2007, 7:328-337.
44. Hanekom M., et al. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis (Edinb.) 2011, 91:510-523.
45. Ford C.B., et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat. Genet. 2013, 45:784-790.
46. Comas I., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012, 44:106-110.
47. de Vos M., et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob. Agents Chemother. 2013, 57:827-832.
48. Paterson G.K., et al. The emergence of mecC methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2014, 22:42-47.
49. Köser C.U., et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med. 2013, 369:290-292.
50. Alexander D.C., et al. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J. Clin. Microbiol. 2012, 50:3726-3728.
51. Warner D.F., Mizrahi V. Complex genetics of drug resistance in Mycobacterium tuberculosis. Nat. Genet. 2013, 45:1107-1108.
52. Sun G., et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J. Infect. Dis. 2012, 206:1724-1733.
53. Eilertson B., et al. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 2014, 58:3270-3275.
54. Folkvardsen D.B., et al. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis?. J. Clin. Microbiol. 2013, 51:1596-1599.
55. Köser C.U., et al. Comment on: Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array. J. Antimicrob. Chemother. 2014, 69:2298-2299.
56. Köser C.U., et al. Consequences of whiB7 (Rv3197A) mutations in Beijing genotype isolates of the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 2013, 57:3461.
57. Köser C.U., et al. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay. Tuberculosis (Edinb.) 2014, 94:451-453.
58. Harris S.R., et al. Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study. Lancet Infect. Dis. 2013, 13:130-136.
59. Didelot X., et al. Microevolutionary analysis of Clostridium difficile genomes to investigate transmission. Genome Biol. 2012, 13:R118.
60. Eyre D.W., et al. A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open 2012, 2:e001124.
61. Eyre D.W., et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 2013, 369:1195-1205.
62. Eyre D.W., et al. Comparison of multilocus variable-number tandem-repeat analysis and whole-genome sequencing for investigation of Clostridium difficile transmission. J. Clin. Microbiol. 2013, 51:4141-4149.
63. Eyre D.W., et al. Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. PLoS Comput. Biol. 2013, 9:e1003059.
64. Price J.R., et al. Whole-genome sequencing shows that patient-to-patient transmission rarely accounts for acquisition of Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 2014, 58:609-618.
65. Wilcox M. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland 2011-13 Report 2014, Public Health England.
66. Le V.T., Diep B.A. Selected insights from application of whole-genome sequencing for outbreak investigations. Curr. Opin. Crit. Care 2013, 19:432-439.
67. Stoesser N., et al. Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data. J. Antimicrob. Chemother. 2013, 68:2234-2244.
68. Zankari E., et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. J. Antimicrob. Chemother. 2013, 68:771-777.
69. Gordon N.C., et al. Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing. J. Clin. Microbiol. 2014, 52:1182-1191.
70. Loman N.J., et al. A culture-independent sequence-based metagenomics approach to the investigation of an outbreak of Shiga-toxigenic Escherichia coli O104:H4. JAMA 2013, 309:1502-1510.
71. Hasman H., et al. Rapid whole genome sequencing for the detection and characterization of microorganisms directly from clinical samples. J. Clin. Microbiol. 2014, 52:139-146.
72. Wilson M.R., et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N. Engl. J. Med. 2014, 370:2408-2417.
73. Reuter S., et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern. Med. 2013, 173:1397-1404.
74. Health Protection Agency Potentially Transferable Linezolid Resistance in Enterococcus faecium in the UK (National Resistance Alert: September 2012) 2012, Health Protection Agency.
75. Public Health England UK Standards for Microbiology Investigations. Laboratory Detection and Reporting of Bacteria with Carbapenem-Hydrolysing β-Lactamases (Carbapenemases) 2012, Public Health England.
76. Diene S.M., Rolain J.M. Investigation of antibiotic resistance in the genomic era of multidrug-resistant Gram-negative bacilli, especially Enterobacteriaceae, Pseudomonas and Acinetobacter. Expert Rev. Anti. Infect. Ther. 2013, 11:277-296.
77. Public Health England Acute Trust Toolkit for the Early Detection, Management and Control of Carbapenemase-Producing Enterobacteriaceae 2013, Public Health England.
78. Snitkin E.S., et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci. Transl. Med. 2012, 4:148ra116.
79. López-Camacho E., et al. Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance. J. Antimicrob. Chemother. 2014, 69:632-636.
80. Huang T.W., et al. Copy number change of the NDM-1 sequence in a multidrug-resistant Klebsiella pneumoniae clinical isolate. PLoS ONE 2013, 8:e62774.
81. Gall A., et al. Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J. Clin. Microbiol. 2012, 50:3838-3844.
82. Keeton C. New diagnostic test changes tuberculosis landscape. Bull. World Health Organ 2013, 91:163-164.
83. Walker T.M., et al. Contact investigations for outbreaks of Mycobacterium tuberculosis: advances through whole genome sequencing. Clin. Microbiol. Infect. 2013, 19:796-802.
84. Roetzer A., et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med. 2013, 10:e1001387.
85. Walker T.M., et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-12, with whole pathogen genome sequences: an observational study. Lancet Respir. Med. 2014, 2:285-292.
86. Public Health England Collaborative Tuberculosis Strategy for England 2014 to 2019 2014, Public Health England.
87. Pedrazzoli D., et al. Tuberculosis in the UK: 2013 Report 2013, Public Health England.
88. Eyre D.W., Walker A.S. Clostridium difficile surveillance: harnessing new technologies to control transmission. Expert Rev. Anti Infect. Ther. 2013, 11:1193-1205.
89. Baker S., et al. Navigating the future of bacterial molecular epidemiology. Curr. Opin. Microbiol. 2010, 13:640-645.
90. Elkins C.A., et al. Genomic paradigms for food-borne enteric pathogen analysis at the USFDA: case studies highlighting method utility, integration and resolution. Food Addit. Contam. Part A 2013, 30:1422-1436.
91. Robinson E.R., et al. Genomics and outbreak investigation: from sequence to consequence. Genome Med. 2013, 5:36.
92. Price J., et al. The usefulness of whole genome sequencing in the management of Staphylococcus aureus infections. Clin. Microbiol. Infect. 2013, 19:784-789.
93. Aarestrup F.M., et al. Integrating genome-based informatics to modernize global disease monitoring, information sharing, and response. Emerg. Infect. Dis. 2012, 18:e1.
94. Joensen K.G., et al. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. J. Clin. Microbiol. 2014, 52:1501-1510.
95. Fricke W.F., Rasko D.A. Bacterial genome sequencing in the clinic: bioinformatic challenges and solutions. Nat. Rev. Genet. 2014, 15:49-55.
96. Wyres K.L., et al. WGS analysis and interpretation in clinical and public health microbiology laboratories: What are the requirements and how do existing tools compare?. Pathogens 2014, 3:437-458.
97. Ängeby K., et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ. 2012, 90:693-698.
98. Kuper K.M., et al. Antimicrobial susceptibility testing: a primer for clinicians. Pharmacotherapy 2009, 29:1326-1343.
99. Rinder H. Hetero-resistance: an under-recognised confounder in diagnosis and therapy?. J. Med. Microbiol. 2001, 50:1018-1020.
100. Cahill M.J., et al. Read length and repeat resolution: exploring prokaryote genomes using next-generation sequencing technologies. PLoS ONE 2010, 5:e11518.